DiagnosTear Overview
DiagnosTear specializes in technology for the diagnosis and treatment of dry eye syndrome. The company is developing an assay designed to facilitate the diagnosis, treatment, and monitoring of dry eye syndrome by examining certain parameters in tear fluid. DiagnosTears TeaRx assay is based on various reagents that create color reactions when coming into contact with tear film, allowing for a semi-quantitative assessment of the parameters that define the syndrome. Information on the parameters assists in the diagnosis of the syndrome and enables a better, more informed selection of treatment and monitoring options. TeaRx enables the monitoring and screening of the condition by examining up to five different varieties of tear fluid. The test is carried out through the use of a simple device that is placed under the lower eyelid to absorb the tear fluid. DiagnosTear is an XLVision Sciences company and a fully owned subsidiary of BioLight.
Cumulative Funding Raised Over Time ($)
$700KJun 2025
$4.5MOct 2020
Latest News
growth-positive
DiagnosTear Technologies Inc. Announces Upsizing of Private Placement of Units
DiagnosTear Technologies Inc., an ophthalmic company, announced an increase in its non-brokered private placement offering to up to 2,000,000 units, aiming to raise $1,000,000. Each unit consists of one common share and one warrant, with the warrant exercisable at $1.00 for 18 months. The funds will support working capital and general corporate purposes. The offering is expected to close by November 5, 2025, subject to compliance with Canadian Securities Exchange requirements. DiagnosTear is known for its TeaRx™ technology, a diagnostic platform for ophthalmic pathologies, including a CE-IVD and Israeli MoH-approved test for Dry Eye Syndrome. The product is not yet FDA-cleared, and the company is developing additional tests for other eye conditions.
PIPE/PO
growth-positive
DiagnosTear Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement
DiagnosTear Technologies Inc. has announced the listing of its common shares on the Frankfurt Stock Exchange, marking a significant milestone in its expansion into European capital markets. This move is expected to enhance the companys visibility and trading liquidity, particularly in a region known for its focus on healthcare innovation. Additionally, DiagnosTear has engaged bullVestor Medien GmbH for marketing services to support its presence in the German market. The agreement with bullVestor, valued at €300,000, aims to increase awareness and engagement with European investors. The listing and marketing efforts are part of DiagnosTears strategy to strengthen its international presence and foster relationships with institutional and retail investors across Europe.
Public TradingPartners
growth-positive
DiagnosTear Technologies Announces $700,000 Private Placement to Enhance Financial Position - TipRanks.com
DiagnosTear Technologies, Inc., a company specializing in ophthalmic diagnostic solutions, announced a non-brokered private placement to raise $700,000 through the sale of 1,400,000 units at $0.50 per unit. Each unit includes one common share and one warrant, exercisable at $1.00 within 18 months. The funds will be used for working capital and general corporate purposes, supporting the companys development of diagnostic solutions in the ophthalmic industry. DiagnosTears flagship technology, TeaRx™, is a diagnostic platform for rapid, Point-of-Care Testing of ophthalmic pathologies, and the company is expanding its pipeline to include tests for various eye conditions.
Investment
growth-positive
Canadian Securities Exchange Reports 2024 Performance Figures
The Canadian Securities Exchange (CSE) reported strong growth in financing activity for 2024, with a significant increase in the number of financings and total capital raised compared to 2023. The CSE introduced 45 new corporate listings, including 11 IPOs, and completed 1,140 financings raising $2.1 billion. Trading activity also increased, with 13.1 billion shares traded and a trading value of $4.0 billion. The CSEs membership in the World Federation of Exchanges and participation in the upcoming Vancouver Resource Investment Conference highlight its efforts to strengthen its position. The CSEs growth is attributed to interest rate cuts and high metal prices, which have fueled investor interest.
Public Trading
growth-positive
Canadian Securities Exchange Welcomes Listing of DiagnosTear Technologies Inc
DiagnosTear Technologies Inc., an Israel-based ophthalmic company, has been listed on the Canadian Securities Exchange (CSE) under the symbol DTR. The company specializes in developing and commercializing diagnostic solutions for eye diseases, focusing on its TeaRx™ technology for rapid, point-of-care testing through tear fluid. DiagnosTear aims to become a global leader in ocular disease diagnostics, particularly for conditions like dry eye and red eye. The listing on the CSE marks a significant step in the companys growth, providing access to public capital markets and enhancing its global liquidity.
Public Trading
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $4.55M |
| Last funding | $700K |
| Stage | Public |
| Rounds | 4 |
| Investors | 2 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | bio-light.co.il/diagnos-tear/ |
Locations
Kiryat Atidim, Tel Aviv-Yafo, Israel
Photos & Videos
1 item(s)
DiagnosTear Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesDiagnostics DevicesTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
—Tags (10)
eye-diseasesophthalmologydiagnosticsmedical-devicesnon-invasivemonitoringhealthcare-providersmedical-technologiespersonalizationclinicsGeographic Markets
GlobalIndiaDiagnosTear Financials
$4.55M
Total funding
Undisclosed
Capital raised
$700K
Last funding
Public
Funding stage
4
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$700KJun 2025
$4.5MOct 2020
Private Equity Funding
PIPE
Jun 2025
$700K
Undisclosed Round
Oct 2020
$3.85M
Elcam Medical, BIOLIGHT Life Sciences
Non-Equity Funding
GrantEvent
Oct 2015
Undisclosed
Office of the Chief Scientist
GrantEvent
May 2014
Undisclosed
Office of the Chief Scientist
Public Offering / Exit
ReverseMergerEvent
Dec 2024
Undisclosed
DiagnosTear Lifecycle
Cumulative Funding Raised Over Time
$700KJun 2025
$4.5MOct 2020
All Events
PIPE
Jun 2025
$700K
Undisclosed Round
Oct 2020
$3.85M
Elcam Medical, BIOLIGHT Life Sciences
GrantEvent
Oct 2015
Undisclosed
Office of the Chief Scientist
GrantEvent
May 2014
Undisclosed
Office of the Chief Scientist
ReverseMergerEvent
Dec 2024
Undisclosed
DiagnosTear News
10 articles
growth-positive
DiagnosTear Technologies Inc. Announces Upsizing of Private Placement of Units
DiagnosTear Technologies Inc., an ophthalmic company, announced an increase in its non-brokered private placement offering to up to 2,000,000 units, aiming to raise $1,000,000. Each unit consists of one common share and one warrant, with the warrant exercisable at $1.00 for 18 months. The funds will support working capital and general corporate purposes. The offering is expected to close by November 5, 2025, subject to compliance with Canadian Securities Exchange requirements. DiagnosTear is known for its TeaRx™ technology, a diagnostic platform for ophthalmic pathologies, including a CE-IVD and Israeli MoH-approved test for Dry Eye Syndrome. The product is not yet FDA-cleared, and the company is developing additional tests for other eye conditions.
PIPE/PO
growth-positive
DiagnosTear Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement
DiagnosTear Technologies Inc. has announced the listing of its common shares on the Frankfurt Stock Exchange, marking a significant milestone in its expansion into European capital markets. This move is expected to enhance the companys visibility and trading liquidity, particularly in a region known for its focus on healthcare innovation. Additionally, DiagnosTear has engaged bullVestor Medien GmbH for marketing services to support its presence in the German market. The agreement with bullVestor, valued at €300,000, aims to increase awareness and engagement with European investors. The listing and marketing efforts are part of DiagnosTears strategy to strengthen its international presence and foster relationships with institutional and retail investors across Europe.
Public TradingPartners
growth-positive
DiagnosTear Technologies Announces $700,000 Private Placement to Enhance Financial Position - TipRanks.com
DiagnosTear Technologies, Inc., a company specializing in ophthalmic diagnostic solutions, announced a non-brokered private placement to raise $700,000 through the sale of 1,400,000 units at $0.50 per unit. Each unit includes one common share and one warrant, exercisable at $1.00 within 18 months. The funds will be used for working capital and general corporate purposes, supporting the companys development of diagnostic solutions in the ophthalmic industry. DiagnosTears flagship technology, TeaRx™, is a diagnostic platform for rapid, Point-of-Care Testing of ophthalmic pathologies, and the company is expanding its pipeline to include tests for various eye conditions.
Investment
growth-positive
Canadian Securities Exchange Reports 2024 Performance Figures
The Canadian Securities Exchange (CSE) reported strong growth in financing activity for 2024, with a significant increase in the number of financings and total capital raised compared to 2023. The CSE introduced 45 new corporate listings, including 11 IPOs, and completed 1,140 financings raising $2.1 billion. Trading activity also increased, with 13.1 billion shares traded and a trading value of $4.0 billion. The CSEs membership in the World Federation of Exchanges and participation in the upcoming Vancouver Resource Investment Conference highlight its efforts to strengthen its position. The CSEs growth is attributed to interest rate cuts and high metal prices, which have fueled investor interest.
Public Trading
growth-positive
Canadian Securities Exchange Welcomes Listing of DiagnosTear Technologies Inc
DiagnosTear Technologies Inc., an Israel-based ophthalmic company, has been listed on the Canadian Securities Exchange (CSE) under the symbol DTR. The company specializes in developing and commercializing diagnostic solutions for eye diseases, focusing on its TeaRx™ technology for rapid, point-of-care testing through tear fluid. DiagnosTear aims to become a global leader in ocular disease diagnostics, particularly for conditions like dry eye and red eye. The listing on the CSE marks a significant step in the companys growth, providing access to public capital markets and enhancing its global liquidity.
Public Trading
growth-positive
Canadian Securities Exchange Welcomes Listing of DiagnosTear Technologies Inc
DiagnosTear Technologies Inc., an Israel-based ophthalmic company, has successfully listed its common shares on the Canadian Securities Exchange (CSE) under the symbol DTR. The company specializes in developing diagnostic solutions for eye diseases, utilizing its TeaRx™ technology for rapid, point-of-care testing through tear fluid. The listing marks a significant step for DiagnosTear as it aims to become a global leader in ocular disease diagnostics. The CSE is recognized for supporting emerging companies with innovative technologies, and DiagnosTears listing is expected to enhance its visibility and access to public capital markets. The companys focus on non-invasive, easy-to-use diagnostic tools aligns with its goal of providing personalized treatment options for conditions like dry eye and red eye.
Public Trading
growth-positive
Diagnostear, a subsidiary of BioLight Life Sciences Ltd, signed a binding Letter of Intent for merger, capital raise and listing on the Canadian Securities Exchange
BioLight, a company specializing in investments in biomed companies focusing on eye diseases, announced that its subsidiary, Diagnostear, has entered into a binding LOI for a merger with a Canadian corporation. This merger will allow Diagnostear to list its shares on the Canadian Securities Exchange with an estimated value of US$ 33.5 million. BioLight will hold approximately 50% of the shares in the merged company. As part of the merger, Diagnostear will raise US$ 1 million, and the Canadian corporation will raise US$ 2.5 million. The funds will support Diagnostears business plan, including the development of eye tests based on tear fluid analysis. The merger aims to enhance Diagnostears market presence and product development.
Acquired-byInvestment
growth-positive
ביולייט מגייסת נבדק ראשון בהודו לניסוי קליני לאבחון מחלות עיניים
Israeli company BioLight announced that its subsidiary DiagnosTear has enrolled the first participant in a clinical trial in India. The trial is part of a commercial collaboration agreement with an international pharmaceutical company and the LV Prasad Eye Institute. DiagnosTear, which is 82% owned by BioLight, develops the TeaRx technology for diagnosing eye diseases by analyzing tear fluid composition and personalizing and monitoring treatment for dry eye syndrome. The clinical trial aims to evaluate the products capabilities in diagnosing and treating patients with dry eye syndrome and will involve approximately 600 participants over a period of up to 6 months.
Partners
growth-positive
BioLight's TeaRx Multi-Parameter Diagnostic Assays to be Used in Dry Eye Syndrome Drug Trial
BioLights subsidiary, DiagnosTear, has signed a services agreement with a pharmaceuticals company for the use of its TeaRx diagnostic assays in a clinical trial for dry eye syndrome. This marks the first time TeaRx will be used in a drug trial. The collaboration may lead to a joint-development project for a potential companion diagnostics solution. BioLight aims to address the unmet medical need for personalized treatment of DES. Dry eye syndrome affects millions of people worldwide. BioLights key investors include Mr. Israel Makov, Mr. Dilip Shanghvi, Mr. Dan Oren, and Rock-One.
Partners
growth-positive
BioLight Announces Start of Clinical Study with DiagnosTear Dry Eye Syndrome Diagnostic Assay
BioLight Life Sciences Investments Ltd. has announced that DiagnosTear Ltd. has received all necessary approvals from Sheba Medical Center near Tel Aviv to begin a clinical study with its TeaRx, point-of-care Dry Eye Syndrome diagnostic assay. The study aims to validate the effectiveness of the test methods developed by DiagnosTear. The diagnostic assay has stimulated strong interest among leading ophthalmic companies and key opinion leaders worldwide. DiagnosTear is preparing to add another center in Israel to the clinical study soon and expects to report its results in the fourth quarter of 2014.
InvestmentPartners
Employee Info
| Employees (range) | 1-10 |
| Exact count | 8 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 6 classification IDs that could be used for matching.
DiagnosTear Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 514733765 |
| Crunchbase | diagnostear |
| Phone | +972732753400 |
| Creator | Arielle Smolin |
| Creator email | ari.smolin@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-12-08T00:00:00.000Z |
| Created | 2014-07-08T00:00:00.000Z |
| Status detail | Public on CSE on Dec, 2024; |